87 related articles for article (PubMed ID: 26431491)
1. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations.
Jiang Y; Malouf GG; Zhang J; Zheng X; Chen Y; Thompson EJ; Weinstein JN; Yuan Y; Spano JP; Broaddus R; Tannir NM; Khayat D; Lu KH; Su X
Oncotarget; 2015 Nov; 6(37):39865-76. PubMed ID: 26431491
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation and nuclear localization of beta-catenin in endometrial carcinoma in response to progesterone therapy.
Saegusa M; Hamano M; Kuwata T; Yoshida T; Hashimura M; Akino F; Watanabe J; Kuramoto H; Okayasu I
Cancer Sci; 2003 Jan; 94(1):103-11. PubMed ID: 12708483
[TBL] [Abstract][Full Text] [Related]
3. DNA Methylation Signature of Synchronous Endometrioid Endometrial and Ovarian Carcinomas.
Hsu Lin L; Allison DHR; Turashvili G; Vasudevaraja V; Tran I; Serrano J; Weigelt B; Ladanyi M; Abu-Rustum NR; Snuderl M; Chiang S
Mod Pathol; 2023 Nov; 36(11):100321. PubMed ID: 37652400
[TBL] [Abstract][Full Text] [Related]
4. Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer.
Yang S; Jia Y; Liu X; Winters C; Wang X; Zhang Y; Devor EJ; Hovey AM; Reyes HD; Xiao X; Xu Y; Dai D; Meng X; Thiel KW; Domann FE; Leslie KK
Oncotarget; 2014 Oct; 5(20):9783-97. PubMed ID: 25229191
[TBL] [Abstract][Full Text] [Related]
5. PAX2 is regulated by estrogen/progesterone through promoter methylation in endometrioid adenocarcinoma and has an important role in carcinogenesis via the AKT/mTOR signaling pathway.
Chen H; Li L; Liu H; Qin P; Chen R; Liu S; Xiong H; Li Y; Yang Z; Xie M; Yang H; Jiang Q
J Pathol; 2024 Apr; 262(4):467-479. PubMed ID: 38185904
[TBL] [Abstract][Full Text] [Related]
6. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas.
Jamieson A; Vermij L; Kramer CJH; Jobsen JJ; Jürgemlienk-Schulz I; Lutgens L; Mens JW; Haverkort MAD; Slot A; Nout RA; Oosting J; Carlson J; Howitt BE; Ip PPC; Lax SF; McCluggage WG; Singh N; McAlpine JN; Creutzberg CL; Horeweg N; Gilks CB; Bosse T
Clin Cancer Res; 2023 Dec; 29(23):4949-4957. PubMed ID: 37773079
[TBL] [Abstract][Full Text] [Related]
7. KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomas.
Rudd ML; Hansen NF; Zhang X; Urick ME; Zhang S; Merino MJ; ; Mullikin JC; Brody LC; Bell DW
PLoS One; 2022; 17(1):e0251286. PubMed ID: 35081118
[TBL] [Abstract][Full Text] [Related]
8. Participation of Long Noncoding RNA
Liu L; Zhao J; Guo H; Jia J; Shi L; Ma J; Zhang Z
Cancer Biother Radiopharm; 2024 Mar; ():. PubMed ID: 38512300
[No Abstract] [Full Text] [Related]
9. Three classes of response elements for human PRC2 and MLL1/2-Trithorax complexes.
Du J; Kirk B; Zeng J; Ma J; Wang Q
Nucleic Acids Res; 2018 Sep; 46(17):8848-8864. PubMed ID: 29992232
[TBL] [Abstract][Full Text] [Related]
10. Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular Classification.
Zammarrelli WA; Kim SH; Da Cruz Paula A; Rios-Doria EV; Ehmann S; Yeoshoua E; Hanlon EJ; Zhou Q; Iasonos A; Alektiar KM; Aghajanian C; Makker V; Leitao MM; Abu-Rustum NR; Ellenson LH; Weigelt B; Mueller JJ
JCO Precis Oncol; 2022 Oct; 6():e2200194. PubMed ID: 36240474
[TBL] [Abstract][Full Text] [Related]
11.
Li L; Yue P; Zhu J; Li L; Wang K; Yuan G; Song Y
Cancer Invest; 2024 Apr; 42(4):297-308. PubMed ID: 38666471
[TBL] [Abstract][Full Text] [Related]
12. Identification of a gene expression signature for survival prediction in type I endometrial carcinoma.
Levan K; Partheen K; Osterberg L; Olsson B; Delle U; Eklind S; Horvath G
Gene Expr; 2010; 14(6):361-70. PubMed ID: 20635577
[TBL] [Abstract][Full Text] [Related]
13. Nuclear Long Noncoding RNAs: Key Regulators of Gene Expression.
Sun Q; Hao Q; Prasanth KV
Trends Genet; 2018 Feb; 34(2):142-157. PubMed ID: 29249332
[TBL] [Abstract][Full Text] [Related]
14. Obesity and altered angiogenic-related gene expression in endometrial cancer.
Cobb LP; Siamakpour-Reihani S; Zhang D; Qin X; Owzar K; Zhou C; Conrads TP; Maxwell GL; Darcy KM; Bateman NW; Litzi T; Bae-Jump V; Secord AA
Gynecol Oncol; 2021 Nov; 163(2):320-326. PubMed ID: 34538531
[TBL] [Abstract][Full Text] [Related]
15. MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization.
Walker CJ; Rush CM; Dama P; O'Hern MJ; Cosgrove CM; Gillespie JL; Zingarelli RA; Smith B; Stein ME; Mutch DG; Shakya R; Chang CW; Selvendiran K; Song JW; Cohn DE; Goodfellow PJ
J Natl Cancer Inst; 2018 May; 110(5):517-526. PubMed ID: 29155953
[TBL] [Abstract][Full Text] [Related]
16. Proteogenomic Characterization of Endometrial Carcinoma.
Dou Y; Kawaler EA; Cui Zhou D; Gritsenko MA; Huang C; Blumenberg L; Karpova A; Petyuk VA; Savage SR; Satpathy S; Liu W; Wu Y; Tsai CF; Wen B; Li Z; Cao S; Moon J; Shi Z; Cornwell M; Wyczalkowski MA; Chu RK; Vasaikar S; Zhou H; Gao Q; Moore RJ; Li K; Sethuraman S; Monroe ME; Zhao R; Heiman D; Krug K; Clauser K; Kothadia R; Maruvka Y; Pico AR; Oliphant AE; Hoskins EL; Pugh SL; Beecroft SJI; Adams DW; Jarman JC; Kong A; Chang HY; Reva B; Liao Y; Rykunov D; Colaprico A; Chen XS; Czekański A; Jędryka M; Matkowski R; Wiznerowicz M; Hiltke T; Boja E; Kinsinger CR; Mesri M; Robles AI; Rodriguez H; Mutch D; Fuh K; Ellis MJ; DeLair D; Thiagarajan M; Mani DR; Getz G; Noble M; Nesvizhskii AI; Wang P; Anderson ML; Levine DA; Smith RD; Payne SH; Ruggles KV; Rodland KD; Ding L; Zhang B; Liu T; Fenyö D;
Cell; 2020 Feb; 180(4):729-748.e26. PubMed ID: 32059776
[TBL] [Abstract][Full Text] [Related]
17. Cancer subtypes classification using long non-coding RNA.
Flippot R; Malouf GG; Su X; Mouawad R; Spano JP; Khayat D
Oncotarget; 2016 Aug; 7(33):54082-54093. PubMed ID: 27340923
[TBL] [Abstract][Full Text] [Related]
18. The mutational landscape of chromatin regulatory factors across 4,623 tumor samples.
Gonzalez-Perez A; Jene-Sanz A; Lopez-Bigas N
Genome Biol; 2013; 14(9):r106. PubMed ID: 24063517
[TBL] [Abstract][Full Text] [Related]
19. The DNA Damage Response (DDR) landscape of endometrial cancer defines discrete disease subtypes and reveals therapeutic opportunities.
Zhang X; Joseph S; Wu D; Bowser JL; Vaziri C
bioRxiv; 2023 Nov; ():. PubMed ID: 38045328
[TBL] [Abstract][Full Text] [Related]
20. The DNA Damage Response (DDR) landscape of endometrial cancer defines discrete disease subtypes and reveals therapeutic opportunities.
Zhang X; Joseph S; Wu D; Bowser JL; Vaziri C
NAR Cancer; 2024 Jun; 6(2):zcae015. PubMed ID: 38596432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
